# OnCo record sarc028 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/sarc028/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "sarc028", "NCT02301039" ;
  schema:name "SARC028"@en ;
  schema:description "SARC028 tested the immunotherapy pembrolizumab across the common sarcoma types and found that it works in some, undifferentiated pleomorphic sarcoma above all, and barely at all in bone sarcomas such as osteosarcoma and Ewing sarcoma."@en ;
  schema:url <https://onco.cc/trials/sarc028/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02301039> ;
  onco:status "mixed" ;
  onco:tag "subtype-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/>, <https://onco.cc/cancers/liposarcoma/>, <https://onco.cc/cancers/osteosarcoma/>, <https://onco.cc/cancers/ewing-sarcoma/>, <https://onco.cc/cancers/sarcoma/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:people <https://onco.cc/people/hussein-tawbi/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017/> .